Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ER alerts may help tame type 2 diabetes

NCT ID NCT06899191

Knowledge-focused Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed trial tested whether electronic alerts in the emergency room can improve care for people with type 2 diabetes. The alerts prompted doctors to order an A1c test when blood sugar was very high, and to consider admitting the patient for better diabetes management. Researchers compared outcomes before and after the alerts were introduced in 300 ER patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Electronic health record prompts
What this could lead to
If successful, this approach could help ER doctors start diabetes treatment sooner and connect patients to follow-up care faster.
What could go wrong
This is a small, completed study comparing outcomes before and after the alerts were introduced, so results may not apply to other hospitals or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

300 people

The number who actually took part.

Started

Mar 2025

Finished

Apr 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Moderate hyperglycemia, (glucose ≥250 mg/dL) * Patients who arrive in the emergency department * Not pregnant or peri-partum * Not SARS-COV-2 PCR positive in past 7 days Exclusion Criteria: * Diabetic ketoacidosis (pH \< 7.20, HCO3 \< 15, AG \> 25) * Diabetic foot ulcer or skin complications * Hyperglycemic hyperosmolar state with neurologic impairment * Patients who leave against medical advice (AMA), elope from the ED, or are transferred to another facility

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hyperglycemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hyperglycemia type 1 diabetes mellitus type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hyperglycemia Insulin dependent diabetes Type 2 diabetes Type 2 diabetes mellitus (T2DM)

Contacts and locations

Locations

  • Rutgers, Robert Wood Johnson Hospital

    New Brunswick, New Jersey, 08901, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.